WHO WE ARE:
CSL Behring is a global biotechnology leader focused on serving patients’ needs. Our scientists use the latest technologies to develop and deliver innovative therapies that are used to treat serious and rare diseases, including immunodeficiency and autoimmune diseases, hereditary and acquired bleeding disorders, chronic inflammatory demyelinating polyneuropathy (CIDP), hereditary angioedema (HAE), and Alpha 1 antitrypsin deficiency, as well as transplantation and critical care.
We offer one of the most comprehensive portfolios of high-quality, technically advanced immunoglobulin (Ig) therapies and we are the leading Ig manufacturer in the world. Our treatments include Hizentra® (www.hizentra.com/pi) – indicated for primary immune deficiency (PI) with subcutaneous infusions, which means you can self-administer by infusing just under the skin, not into a vein, after receiving training from your doctor – and Privigen® (www.privigen.com), the only IVIg stabilized with proline and used to treat PI. To read more about our promise to patients and how we can help, please visit www.cslbehring.com/patients.